Role of Cresp® in the management of chemotherapy-induced anemia in cancer patients: A real-world clinical practice audit

Role of Cresp® in the management of chemotherapy-induced anemia in cancer patients: A real-world clinical practice audit: Ghanshyam Biswas, Avinash Pandey, Nikhil Ghadyalpatil, Nilesh Lokeshwar, Boben Thomas, Anita Ramesh, Yogesh Arora, Chandragouda Dodagoudar, Vibha Naik, Ashish Joshi, Indranil Ghosh, Rakesh Roy, Medhi Kunjahari, Tejinder Singh, Palanki Dattatreya Satya, Sachin Hingmire, Purvish M Parikh



South Asian Journal of Cancer 2020 9(1):59-61



Introduction: Anemia is a common, underestimated problem in cancer patients receiving myelosuppressive chemotherapy and has significant adverse effect on the quality of life and outcome. Darbepoetin has been shown to be effective in this setting, but controversy surrounds it actual use. Methods: We analyzed prospectively collected clinical practice data of patients receiving darbepoetin in a real-world setting for this retrospective audit. Patients with baseline hemoglobin (Hb) of <11 g/dl were included in this analysis. Their medical records were audited using a predetermined 35-point pro forma. Results: There were a total of 274 patients with advanced cancer receiving myelosuppressive chemotherapy who had baseline Hb <11 g/dl and who were given darbepoetin. Head-and-neck squamous cell carcinoma, lung cancer, and breast cancer were the most common cancers. Their median baseline Hb was 8.9 g/dl which rose to 11.2 g/dl at the end of commenced therapy, along with improved symptomatology. There were no new toxicities, and only two patients required discontinuation of darbepoetin due to toxicity. Conclusion: Darbepoetin is safe and effective in the prevention and management of anemia among patients receiving myelosuppressive chemotherapy.